论文部分内容阅读
氟班色林(flibanserin)是由德国勃林格殷格翰(Boehringer Ingelheim)制药公司组织开发,之后由美国萌芽(Sprout Pharmaceuticals)制药公司收购并提交申请,于2015年8月18日获得美国食品和药品监督管理局(FDA)批准上市,商品名为Addyi,该药用于治疗绝经前女性性功能障碍(HSDD),它是FDA批准的首个用于治
Flibanserin was developed by a pharmaceutical company in Boehringer Ingelheim, Germany before being acquired and submitted by Sprout Pharmaceuticals, Inc., USA, on August 18, 2015 for the US Food and Drugs The Food and Drug Administration (FDA) approved the marketed drug, Addyi, for the treatment of pre-menopausal female sexual dysfunction (HSDD), the first of its kind approved by the FDA